Australia has a unique opportunity to reform the way it evaluates and funds medicines and vaccines, to
ensure that Australians are among the first in the world to access new technologies. This is a policy
objective of the Australian Government that is shared by the medicines industry. Reforms to Australia’s
Pharmaceutical Benefits Scheme (PBS) and National Immunisation Program (NIP) are needed so that
Australian patients can access medicines and vaccines like other similar countries.
Australia’s Vaccine Value Chain Conference Outputs
There is an identified need in Australia’s Vaccine Value Chain
